Now that the majority of people living with HIV take combination antiretroviral therapy (ART), the
spectrum of causes of pyrexia of unknown origin (PUO) has changed compared with the pre-ART era.
In these guidelines, we focus on causes and evaluation of PUO among people living with HIV with
CD4 counts <3...
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...
These guidelines provide guidance on the diagnosis of HIV infection, the care of people living
with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection.
They are structured along the continuum of HIV testing, prevention, treatment and care.
This edition updates the 201...
This publication provides guidance on the public health response to pretreatment HIV drug resistance (HIVDR) to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) among people without prior antiretroviral (ARV) drug exposure or people with prior ARV exposure who are initiating or reinitiating first...
These consolidated guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the care of people living with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. They are structured along the continuum of HIV testing, care and treatme...
These recommendations have been developed specifically to address the daily use of antiretrovirals in HIV-uninfected people to block the acquisition of HIV infection. This prevention approach is known as pre-exposure prophylaxis. At this stage evidence is available from studies with two groups: men and t...
